<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201304182496N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-04-28</date_registration>
      <primary_sponsor>Research Vice chancellor of Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of prediction between TIMI (Thrombolysis in Myocardial Infarction) risk score and Modified TIMI risk score in discharged patients from emergency department with atypical chest pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of prediction between TIMI (Thrombolysis in Myocardial Infarction) risk score and Modified TIMI risk score in discharged patients from emergency department with atypical chest pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-06-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>1000</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/2226</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Atypical chest pain.</hc_freetext>
      <i_freetext>Intervention 1: Group I was evaluated using TRS and its patients were discharged in case of having low risk (0-1). All criteria used in TRS method are of equal values and each score one. These criteria include:&#13;
1.	increased cardiac markers: measurements of T troponin 12 hours after the primary chest pain onset&#13;
2.	Ischemic ECG: ECG registration on admission&#13;
3.	Age&gt;65&#13;
4.	Continuous administration of aspirin or history of consumption within previous seven days&#13;
5.	three risk factors: patients should have at least three risk factors including diabetes mellitus, hypertension, hyperlipidemia, and familial history of cardiac diseases in the close relatives before the age of 65 years and smoking history within six previous weeks&#13;
6.	previously-diagnosed cardiovascular stenosis&#13;
7.	severe symptoms: two or more episodes of chest pain within the previous 24 hours or pain duration of more than one hour. Intervention 2: Patients in group II were evaluated regarding their risk factors using MTRS method and were discharged in case of having low risk (0-1). The criteria used in MTRS system are similar to that of TRS. The only difference is scoring is between 0-10 and a score of 5 has been considered for ECG or cardiac biomarker changes (items seven and six) in case of being positive (all together or separately).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Hassan Soleimanpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency Medicine Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz-51664, I.R IRAN. Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>51664</zip>
        <telephone>+98 41 1335 2078</telephone>
        <email>h_mofid1357@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Hassan Soleimanpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency Medicine Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz-51664, I.R IRAN. Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>51664</zip>
        <telephone>+98 41 1335 2078</telephone>
        <email>h_mofid1357@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: All patients with chief complaints of atypical chest pain aged over 25 years old. Exclusion criteria: patients with the diagnosis of STEMI; patients younger than 25 years old; patients being hospitalized due to other reasons including dialysis requirements in CRF patients and myocardial contusion following chest trauma; pregnant women; imprisoned patients and unavailability of the follow-up for patients.</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>100 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I20.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Angina pectoris, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Group I was evaluated using TRS and its patients were discharged in case of having low risk (0-1). All criteria used in TRS method are of equal values and each score one. These criteria include:&#13;
1.	increased cardiac markers: measurements of T troponin 12 hours after the primary chest pain onset&#13;
2.	Ischemic ECG: ECG registration on admission&#13;
3.	Age&gt;65&#13;
4.	Continuous administration of aspirin or history of consumption within previous seven days&#13;
5.	three risk factors: patients should have at least three risk factors including diabetes mellitus, hypertension, hyperlipidemia, and familial history of cardiac diseases in the close relatives before the age of 65 years and smoking history within six previous weeks&#13;
6.	previously-diagnosed cardiovascular stenosis&#13;
7.	severe symptoms: two or more episodes of chest pain within the previous 24 hours or pain duration of more than one hour</i_keyword>
      <i_keyword>Patients in group II were evaluated regarding their risk factors using MTRS method and were discharged in case of having low risk (0-1). The criteria used in MTRS system are similar to that of TRS. The only difference is scoring is between 0-10 and a score of 5 has been considered for ECG or cardiac biomarker changes (items seven and six) in case of being positive (all together or separately).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Atypical chest pain. Timepoint: on arrival and until 12 hours following symptoms onset. Method of measurement: ECGs and cardiac enzymes.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Adverse events. Timepoint: One month after admission in the emergency department. Method of measurement: All patients were followed up regarding the adverse events ((Myocardial Infarction (MI), revascularization and death))  and questionnaire form.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Vice chancellor of Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-01-05</approval_date>
        <contact_name>Research Vice chancellor of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Research Vice chancellor of Tabriz University of Medical Sciences ,Tabriz University of Medical Sciences, Daneshgah Street, Tabriz-51664, I.R IRAN. Tabriz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
